Cash · 2014–2025
Ascendis Pharma cash
$724M+24.5% · FY2025
Ascendis Pharma (ASND) reported $724M in cash for fiscal 2025, +24.5% year on year.
| Fiscal year | Cash | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $724M | +24.5% | Open → |
| FY20242024-12-31 | $581M | +34.1% | Open → |
| FY20232023-12-31 | $433M | −8.7% | Open → |
| FY20222022-12-31 | $474M | −6.1% | Open → |
| FY20212021-12-31 | $505M | −29.5% | Open → |
| FY20202020-12-31 | $717M | +6.7% | Open → |
| FY20192019-12-31 | $672M | +111.2% | Open → |
| FY20182018-12-31 | $318M | +35.8% | Open → |
| FY20172017-12-31 | $234M | +23.3% | Open → |
| FY20162016-12-31 | $190M | +45.9% | Open → |
| FY20152015-12-31 | $130M | +113.9% | Open → |
| FY20142014-12-31 | $60.9M | — | Open → |
Cash — Cash and cash equivalents is money available immediately at the balance-sheet date. It excludes short-term investments, which many large companies hold far more of.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2014–2025 compound annual growth +25.2%
Figures are reported under IFRS in EUR and converted to US dollars at ECB reference rates — fiscal 2025 average 0.885 EUR/$ for income items, year-end 0.851 EUR/$ for balance-sheet items.
Cash at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ascendis Pharma cash |url=https://companiesranked.com/en/company/ascendis-pharma/cash-on-hand |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ascendis Pharma cash. CompaniesRanked. https://companiesranked.com/en/company/ascendis-pharma/cash-on-handBibTeX
@misc{companiesranked-en-company-ascendis-pharma-cash-on-hand-2026,
author = {{CompaniesRanked}},
title = {{Ascendis Pharma cash}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ascendis-pharma/cash-on-hand}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001193125-26-046590 · February 11, 2026
{{cite web |title=Ascendis Pharma cash — 20-F (0001193125-26-046590) |url=https://www.sec.gov/Archives/edgar/data/1612042/000119312526046590/asnd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.